Evaluation of Patient and Physician Reported Reasons for Switching Factor VIII Replacement Therapies (PARkER)
Evaluation of Patient and Physician Reported Reasons for Switching FVIII Replacement Therapies
Sponsor: Bayer
A observational or N/A phase clinical study on Hemophilia A, this trial is completed. The trial is conducted by Bayer and has accumulated 11 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Oct 2018 — Jan 2021 [monthly]
Completed
Status: Recruiting → Completed
-
Sep 2018 — Oct 2018 [monthly]
Recruiting
▶ Show 6 earlier versions
-
Aug 2018 — Sep 2018 [monthly]
Recruiting
-
Jul 2018 — Aug 2018 [monthly]
Recruiting
-
Jun 2018 — Jul 2018 [monthly]
Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Recruiting
Phase: NA → None
-
Mar 2018 — Apr 2018 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Feb 2018 — Mar 2018 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Bayer
For direct contact, visit the study record on ClinicalTrials.gov .